http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
The Effect of Agomelatine in Behavioral and Psychological Symptoms of Dementia
Carol Sheei-Meei Wang(Carol Sheei-Meei Wang ),Kuo-Sheng Cheng(Kuo-Sheng Cheng),Chia-Hung Tang(Chia-Hung Tang),Ming-Chyi Pai(Ming-Chyi Pai),Pai-Lien Chen(Pai-Lien Chen),Pei-Fang Chien(Pei-Fang Chien) 대한정신약물학회 2022 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.20 No.4
Objective: Moderate and severe behavioral and psychological symptoms of dementia (BPSD) often need medical treatment to improve symptoms. Agomelatine is a selective melatonergic (MT1/MT2) agonist that has normalizing effects on disturbed circadian rhythms and disrupted sleep−wake cycles. Its activity of 5HT-2C receptor antagonism is associated with lessening depression and anxiety and increasing slow-wave sleep. Based on past clinical records and current findings it suggests that agomelatine can improve BPSD for patients. This retrospective cohort study was designed to compare the BPSD before and after using agomelatine. Methods: Records of dementia cases who had ever received agomelatine treatment for BPSD in a general hospital setting during the past 2.5 years were identified and reviewed. Scores from before and after 3 months of treatment with agomelatine were collected for Neuropsychiatric Inventory (NPI), Brief Psychiatric Rating Scale (BPRS), and Clinical Global Impression (CGI) to compare and analyze the difference of psychological and behavioral symptoms pre- and post-agomelatine used. Results: Records of 144 cases of dementia with BPSD who had ever used agomelatine from January 2015 to June 2017 were collected. All of the 112 cases had BPRS and CGI scores, of which 75 cases had additional NPI scores. Among these 112 cases, the BPRS and CGI scores were significantly improved in all types of dementia. NPI scores indicated that the use of agomelatine alleviated obvious symptoms and decreased overall distress, especially in the depression/poor mood, anxiety, and sleep/night behavior. Conclusion: It is consistent with an effective result of agomelatine in improving BPSD.
Wu Carol P.,Chang Chia‐Jung,Li Cheng‐Hsun,Wu Yueh‐Lung 한국곤충학회 2021 Entomological Research Vol.51 No.4
The baculovirus expression system has been widely used for industrial-scale production of recombinant proteins. These recombinant proteins are expressed from recombinant baculoviruses carrying an expression cassette for a particular protein. Even though the baculovirus genome can accommodate large fragments of foreign genetic material, it has been shown that defective interfering particles (DIs) are generated over many passages of the recombinant virus. Defective interfering particles can affect the stability of the inserted gene, which can result in sub-optimal expression of the recombinant protein; this can, therefore, have a significant impact on production. The stability of exogenous genes in recombinant viruses over serial passage has not yet been investigated. As such, the present study set out to assess the effect of serial passage on the stability of the expression of an exogenous gene inserted into a recombinant baculovirus and its subsequent recombinant protein yield. To achieve this, a recombinant baculovirus carrying the classical swine fever virus E2 gene was serially passaged up to 20 times. The results showed that the E2 gene expression by the recombinant baculovirus was stable for up to 10 passages without any effect on recombinant E2 production in insect cells.
( Jeffrey M Cohen ),( Carol E Cheng ),( Aieska Desouza ),( Tina R Nandi ),( Elizabeth A Buzney ),( Allison Larson ),( Winston Y Lee ),( Arash Mostaghimi ) 대한피부과학회 2015 Annals of Dermatology Vol.27 No.2
Cutaneous paraneoplastic syndromes comprise a broad spectrum of cutaneous reactions to an underlying malignancy. These dermatoses are not the result of metastatic spread to the skin, but rather a reaction to the presence of malignancy. Cutaneous paraneoplastic syndromes often precede the identification of a malignancy. We describe the case of a 79-year-old man with a six-month history of recalcitrant treatment- resistant dermatitis. A complete blood count test performed at the time of initial presentation was normal. The patient ultimately presented with erythroderma and was diagnosed with acute myeloid leukemia (AML). The evolution of the dermatitis to erythroderma coincided with the clinical presentation of AML, and was therefore considered to be a paraneoplastic syndrome. The patient decided against therapy and died seven weeks after diagnosis. Physicians should consider a cutaneous paraneoplastic syndrome when faced with dynamic recalcitrant dermatoses that are difficult to treat and decide on laboratory testing accordingly. Patients should be evaluated regularly for two to three years after initial diagnosis with a physical exam and review of systems to monitor for signs and symptoms of malignancy.(Ann Dermatol 27(2) 190∼193, 2015)
( Jeffrey M Cohen ),( Carol E Cheng ),( Aieska Desouza ),( Tina R Nandi ),( Elizabeth A Buzney ),( Allison Larson ),( Winston Y Lee ),( Arash Mostaghimi ) 대한피부과학회 2015 Annals of Dermatology Vol.27 No.3
Cutaneous paraneoplastic syndromes comprise a broad spectrum of cutaneous reactions to an underlying malignancy. These dermatoses are not the result of metastatic spread to the skin, but rather a reaction to the presence of malignancy. Cutaneous paraneoplastic syndromes often precede the identification of a malignancy. We describe the case of a 79-year-old man with a six-month history of recalcitrant treatment- resistant dermatitis. A complete blood count test performed at the time of initial presentation was normal. The patient ultimately presented with erythroderma and was diagnosed with acute myeloid leukemia (AML). The evolution of the dermatitis to erythroderma coincided with the clinical presentation of AML, and was therefore considered to be a paraneoplastic syndrome. The patient decided against therapy and died seven weeks after diagnosis. Physicians should consider a cutaneous paraneoplastic syndrome when faced with dynamic recalcitrant dermatoses that are difficult to treat and decide on laboratory testing accordingly. Patients should be evaluated regularly for two to three years after initial diagnosis with a physical exam and review of systems to monitor for signs and symptoms of malignancy. (Ann Dermatol 27(2) 190∼193, 2015)